Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial - PubMed (original) (raw)

Randomized Controlled Trial

Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial

Kaiyun Chen et al. PLoS One. 2013.

Abstract

Background: Tumor recurrence is a major problem after curative resection of hepatocellular carcinoma (HCC). The current study evaluated the effects of adjuvant iodine-125 ((125)I) brachytherapy on postoperative recurrence of HCC.

Methodology/principal findings: From July 2000 to June 2004, 68 HCC patients undergoing curative hepatectomy were randomly assigned into a (125)I adjuvant brachytherapy group (n = 34) and a group of best care (n = 34). Patients in the (125)I adjuvant brachytherapy group received (125)I seed implantation on the raw surface of resection. Patients in the best care control group received identical treatments except for the (125)I seed implantation. Time to recurrence (TTR) and 1-, 3- and 5-year overall survival (OS) were compared between the two groups. The follow-up ended in January 2010, and lasted for 7.7-106.4 months with a median of 47.6 months. TTR was significantly longer in the (125)I group (mean of 60.0 months vs. 36.7 months in the control). The 1-, 3- and 5-year recurrence-free rates of the (125)I group were 94.12%, 76.42%, and 73.65% vs. 88.24%, 50.00%, and 29.41% compared with the control group, respectively. The 1-, 3- and 5-year OS rates of the (125)I group were 94.12%, 73.53%, and 55.88% vs. 88.24%, 52.94%, and 29.41% compared with the control group, respectively. The (125)I brachytherapy decreased the risk of recurrence (HR = 0.310) and the risk of death (HR = 0.364). Most frequent adverse events in the (125)I group included nausea, vomiting, arrhythmia, decreased white blood cell and/or platelet counts, and were generally mild and manageable.

Conclusions/significance: Adjuvant (125)I brachytherapy significantly prolonged TTR and increased the OS rate after curative resection of HCC.

Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000081011.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. A flow chart of the trial.

Figure 2

Figure 2. Time to recurrence curves.

Time to recurrence in patients in the adjuvant 125I brachytherapy vs. in the control group, log-rank, X 2 = 7.04, p = 0.008.

Figure 3

Figure 3. Overall survival curves.

OS in patients in the adjuvant 125I brachytherapy vs. in the control group, log-rank, X 2 = 4.97, p = 0.026.

References

    1. Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23: 1535–1547. - PubMed
    1. Chang CH, Chau GY, Lui WY, Tsay SH, King KL, et al.. (2004) Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 139: 320–325, 326. - PubMed
    1. Tung-Ping PR, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10–24. - PMC - PubMed
    1. Lai EC, Lo CM, Fan ST, Liu CL, Wong J (1998) Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133: 183–188. - PubMed
    1. Takenaka K, Yoshida K, Nishizaki T, Korenaga D, Hiroshige K, et al.. (1995) Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 169: 400–404, 405. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources